Iol Chemicals And Pharmaceuticals Limited

Profit volatility out of line with revenue: net profit fell from ₹30 Cr (Sep 2025) to ₹21 Cr (Dec 2025) despite 2% revenue growth, raising questions about cost control.

Operating margin swings 9.87% to 14.94% across recent quarters, suggesting seasonal factors or underlying cost/mix instability.

Valuation headwind: PE 28.91 is elevated; verify whether near-term earnings growth justifies the multiple or if pharma sector headwinds are being overlooked.

Low ROE of 7.9% questions capital allocation; despite low debt (D/E 0.07), returns on deployed equity remain modest.

Revenue grew 33% in 9 months to ₹756.26 Cr; verify whether volume, pricing, or new products drove this and if sustainable.

OPM recovered 4pp from 9.87% (Dec 2025) to 13.69% (Jun 2026); verify whether cost reduction, pricing, or scale drove improvement.

FII shareholding nearly tripled from 1.72% to 4.87% (Jun 2026), signaling institutional confidence; verify thesis behind rerating.

Promoter stake increased 4.8pp to 62.28%; verify whether this reflects growth confidence or consolidation strategy.